Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
PAK6 encodes a member of a family of p21-stimulated serine/threonine protein kinases, which contain an amino-terminal Cdc42/Rac interactive binding (CRIB) domain and a carboxyl-terminal kinase domain. Zusätzlich bieten wir Ihnen P21-Activated Kinase 6 Proteine (10) und viele weitere Produktgruppen zu diesem Protein an.
Showing 10 out of 164 products:
Human Polyclonal PAK6 Primary Antibody für IHC, ELISA - ABIN1002959
Jaffer, Chernoff: p21-activated kinases: three more join the Pak. in The international journal of biochemistry & cell biology 2002
Show all 3 Pubmed References
Dog (Canine) Polyclonal PAK6 Primary Antibody für IHC (p) - ABIN4343483
Kwek, Dao, Roy, Hou, Alajajian, Simko, Small, Fong: Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients. in Journal of immunology (Baltimore, Md. : 1950) 2012
Human Polyclonal PAK6 Primary Antibody für ELISA, ICC - ABIN4343485
Raja, Sahasrabuddhe, Radhakrishnan, Syed, Solanki, Puttamallesh, Balaji, Nanjappa, Datta, Babu, Renuse, Patil, Izumchenko, Prasad, Chang, Rangarajan, Sidransky, Pandey, Gowda, Chatterjee: Chronic exposure to cigarette smoke leads to activation of p21 (RAC1)-activated kinase 6 (PAK6) in non-small cell lung cancer cells. in Oncotarget 2016
RhoD recruits Pak6 to the plasma membrane to antagonize RhoC (zeige RHOC Antikörper) signaling during cell contraction and blebbing
PAK6 localization to cell-cell adhesions is Cdc42 (zeige CDC42 Antikörper)-dependent
p21-activated kinase 6 (PAK6) as a novel interactor of leucine-rich repeat kinase 2 (LRRK2 (zeige LRRK2 Antikörper)), a kinase involved in Parkinson's disease
PAK6 is directly targeted by miR (zeige MLXIP Antikörper)-328. miR (zeige MLXIP Antikörper)-328 inhibits cell growth and promotes cell apoptosis in prostate cancer cells.
negative correlation between PAK6 and EZH2 (zeige EZH2 Antikörper) expression was observed in hepatoma tissues from HCC (zeige FAM126A Antikörper) patients. These data identified the tumor suppressive role and potential underlying mechanism of PAK6 in hepatocarcinogenesis
the results of the present study suggested that miR (zeige MLXIP Antikörper)-429 inhibits the migration and invasion of colon cancer cells, partly at least, by mediating the expression of PAK6, as well as the activity of cofilin (zeige CFL1 Antikörper) signaling
we report that in colon cancer PAK6 promotes tumor progression and chemoresistance both in vitro and in vivo
PAK6 is specifically required for carcinoma cell-cell dissociation downstream of hepatocyte growth factor (HGF (zeige HGF Antikörper)) for both DU145 prostate cancer and HT29 colon cancer cells.
PAK5 plays an essential role in the initiation and progression of hepatocellular carcinoma.
These results demonstrate that androgen-stimulated PAK6 activation is mediated through a direct interaction between AR and PAK6 and PAK6 activation promotes prostate cancer cells motility and invasion.
data suggest that PAK-6 p21 (zeige D4S234E Antikörper)-activated kinase plays a role in weight gain unrelated to exercise and caloric intake
functional deficits in PAK5 (zeige PAK7 Antikörper), PAK6 and PAK5/PAK6 knockout mice
Our results indicate that Pak5 (zeige PAK7 Antikörper) and Pak6 together are not required for viability, but are required for a normal level of locomotion and activity as well as for learning and memory.
This gene encodes a member of a family of p21-stimulated serine/threonine protein kinases, which contain an amino-terminal Cdc42/Rac interactive binding (CRIB) domain and a carboxyl-terminal kinase domain. These kinases function in a number of cellular processes, including cytoskeleton rearrangement, apoptosis, and the mitogen-activated protein (MAP) kinase signaling pathway. The protein encoded by this gene interacts with androgen receptor (AR) and translocates to the nucleus, where it is involved in transcriptional regulation. Changes in expression of this gene have been linked to prostate cancer. Alternative splicing results in multiple transcript variants.
p21(CDKN1A)-activated kinase 6
, serine/threonine-protein kinase PAK 6
, p21-activated kinase 6
, p21 (CDKN1A)-activated kinase 6
, p21 protein (Cdc42/Rac)-activated kinase 6